

Special Issue

Efficacy and Immunology of Nanoparticles Based Vaccines for Poultry and Livestock Infectious Diseases

Message from the Guest Editor

Infectious diseases caused by bacteria, viruses, and parasites are a constant economic threat to the global poultry and livestock industry. Infectious disease infections are not only a problem to animal health but also threaten humans through zoonotic transmission. Vaccination in animals is a safe and effective approach in the control, prevention, and transmission of infections. The traditional infectious disease vaccine requires upgradation to overcome their issues such as non-stability in biological conditions, poor immunogenicity, immune tolerance, side effects, and poor broad protection. Due to their unique physicochemical properties, nanoparticles are used as an adjuvant and/or carrier to improve the efficacy of infectious disease vaccine. With this background, the scope of this special issue is focused on the recent developments in nanoparticles based vaccine preparation for poultry and livestock infectious diseases, vaccine safety and efficacy, vaccine inducing innate and adaptive immune responses and protection, and mechanism of vaccine inducing immune responses.

Guest Editor

Dr. Sankar Renu
Food Animal Health Research Program, The Ohio State University,
Wooster, OH 44691, USA

Deadline for manuscript submissions

closed (31 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/62336

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).